Kamada Ltd. (KMDA)
USD 6.09
(3.05%)
USD 6.09
(3.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -46.43 Million USD | -239.96% |
| 2022 | -13.65 Million USD | -336.91% |
| 2021 | 5.76 Million USD | 108.83% |
| 2020 | -65.25 Million USD | -76.78% |
| 2019 | -36.91 Million USD | -119.54% |
| 2018 | -16.81 Million USD | -57.19% |
| 2017 | -10.69 Million USD | -30.58% |
| 2016 | -8.19 Million USD | -68.59% |
| 2015 | -4.85 Million USD | 31.12% |
| 2014 | -7.05 Million USD | 83.55% |
| 2013 | -42.89 Million USD | -691.56% |
| 2012 | 7.25 Million USD | 474.05% |
| 2011 | -1.93 Million USD | 23.72% |
| 2010 | -2.54 Million USD | 72.92% |
| 2009 | -9.38 Million USD | -233.2% |
| 2008 | 7.04 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -39.09 Million USD | 15.81% |
| 2024 Q2 | -47.83 Million USD | -22.76% |
| 2023 Q2 | -568 Thousand USD | 87.08% |
| 2023 FY | -46.43 Million USD | -239.96% |
| 2023 Q4 | -46.43 Million USD | 0.68% |
| 2023 Q1 | -4.39 Million USD | 67.82% |
| 2023 Q3 | -46.74 Million USD | -8130.28% |
| 2022 Q3 | -9.31 Million USD | -37.06% |
| 2022 Q1 | 2.12 Million USD | -63.1% |
| 2022 Q2 | -6.79 Million USD | -419.56% |
| 2022 FY | -13.65 Million USD | -336.91% |
| 2022 Q4 | -13.65 Million USD | -46.61% |
| 2021 Q3 | -95.32 Million USD | -49.41% |
| 2021 Q1 | -56.78 Million USD | 12.99% |
| 2021 FY | 5.76 Million USD | 108.83% |
| 2021 Q2 | -63.8 Million USD | -12.36% |
| 2021 Q4 | 5.76 Million USD | 106.05% |
| 2020 Q3 | -47.49 Million USD | 9.04% |
| 2020 Q2 | -52.21 Million USD | -18.41% |
| 2020 Q1 | -44.09 Million USD | -19.45% |
| 2020 Q4 | -65.25 Million USD | -37.41% |
| 2020 FY | -65.25 Million USD | -76.78% |
| 2019 FY | -36.91 Million USD | -119.54% |
| 2019 Q1 | -15.97 Million USD | 4.97% |
| 2019 Q2 | -17.92 Million USD | -12.18% |
| 2019 Q3 | -21.39 Million USD | -19.38% |
| 2019 Q4 | -36.91 Million USD | -72.51% |
| 2018 Q4 | -16.81 Million USD | -47.42% |
| 2018 FY | -16.81 Million USD | -57.19% |
| 2018 Q3 | -11.4 Million USD | -6.09% |
| 2018 Q2 | -10.75 Million USD | 31.47% |
| 2018 Q1 | -15.68 Million USD | -46.65% |
| 2017 Q3 | -10.05 Million USD | -11.13% |
| 2017 Q2 | -9.04 Million USD | -0.39% |
| 2017 Q1 | -9.01 Million USD | -10.0% |
| 2017 FY | -10.69 Million USD | -30.58% |
| 2017 Q4 | -10.69 Million USD | -6.41% |
| 2016 Q2 | -5.2 Million USD | 51.33% |
| 2016 Q3 | -4.55 Million USD | 12.46% |
| 2016 Q4 | -8.19 Million USD | -79.73% |
| 2016 Q1 | -10.69 Million USD | -120.17% |
| 2016 FY | -8.19 Million USD | -68.59% |
| 2015 Q4 | -4.85 Million USD | -352.68% |
| 2015 Q1 | -5.6 Million USD | 20.61% |
| 2015 Q2 | 1.11 Million USD | 119.95% |
| 2015 FY | -4.85 Million USD | 31.12% |
| 2015 Q3 | 1.92 Million USD | 72.16% |
| 2014 Q3 | -2.17 Million USD | 73.64% |
| 2014 Q1 | -16.95 Million USD | 60.48% |
| 2014 Q2 | -8.24 Million USD | 51.35% |
| 2014 FY | -7.05 Million USD | 83.55% |
| 2014 Q4 | -7.05 Million USD | -224.47% |
| 2013 FY | -42.89 Million USD | -691.56% |
| 2013 Q3 | -44.92 Million USD | 6.3% |
| 2013 Q2 | -47.93 Million USD | -2134.76% |
| 2013 Q1 | 2.35 Million USD | -67.51% |
| 2013 Q4 | -42.89 Million USD | 4.51% |
| 2012 FY | 7.25 Million USD | 474.05% |
| 2012 Q3 | -15.47 Million USD | 0.0% |
| 2012 Q4 | 7.25 Million USD | 146.87% |
| 2011 FY | -1.93 Million USD | 23.72% |
| 2010 FY | -2.54 Million USD | 72.92% |
| 2009 FY | -9.38 Million USD | -233.2% |
| 2008 FY | 7.04 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 2621.09% |
| Alpha Teknova, Inc. | 1.97 Million USD | 2452.154% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 149.287% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 161.95% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 110.666% |
| Cosmos Health Inc. | 8.59 Million USD | 640.482% |
| Journey Medical Corporation | -9.7 Million USD | -378.232% |
| Embecta Corp. | 1.31 Billion USD | 103.539% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 110.122% |
| Dynavax Technologies Corporation | 106.63 Million USD | 143.542% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 64.51% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 110.73% |
| PainReform Ltd. | -7.95 Million USD | -484.044% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -196.978% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -196.978% |
| SCYNEXIS, Inc. | -19.35 Million USD | -139.956% |
| Safety Shot Inc | -2.28 Million USD | -1932.57% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -392.395% |
| Procaps Group, S.A. | 242.93 Million USD | 119.113% |
| Theratechnologies Inc. | 24.87 Million USD | 286.689% |
| Harrow Health, Inc. | 116.41 Million USD | 139.884% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -1742.521% |
| Biofrontera Inc. | 4.05 Million USD | 1244.761% |
| DURECT Corporation | -7.65 Million USD | -506.631% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -38.49% |
| Cronos Group Inc. | -663.32 Million USD | 93.0% |
| OptiNose, Inc. | 58.06 Million USD | 179.965% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 107.448% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -218.635% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -795.319% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 409.275% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -630.096% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 43551.202% |
| Radius Health, Inc. | 359.28 Million USD | 112.923% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 23644.321% |
| ProPhase Labs, Inc. | 19.23 Million USD | 341.441% |
| Phibro Animal Health Corporation | 454.84 Million USD | 110.208% |
| Procaps Group S.A. | 242.93 Million USD | 119.113% |
| Alvotech | 1.06 Billion USD | 104.363% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 1362.412% |
| Viatris Inc. | 17.13 Billion USD | 100.271% |
| Rockwell Medical, Inc. | 4.45 Million USD | 1142.0% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -852.051% |
| SIGA Technologies, Inc. | -148.68 Million USD | 68.771% |
| Tilray Brands, Inc. | 158.97 Million USD | 129.206% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 138.09% |
| Shineco, Inc. | 29.29 Million USD | 258.522% |
| PetIQ, Inc. | 351.93 Million USD | 113.193% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -1500.299% |
| Incannex Healthcare Limited | -5.48 Million USD | -746.518% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 126.188% |
| Alimera Sciences, Inc. | 55.3 Million USD | 183.949% |
| Silver Spike Investment Corp. | -32.61 Million USD | -42.377% |
| Assertio Holdings, Inc. | -32.52 Million USD | -42.739% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -3018.885% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -817.549% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -864.51% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -465.309% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 1201.056% |
| Hempacco Co., Inc. | 13.61 Million USD | 441.04% |
| Talphera, Inc. | -5.72 Million USD | -711.598% |
| Alvotech | 1.06 Billion USD | 104.363% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 749.846% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 51.989% |
| Currenc Group, Inc. | -16.57 Million USD | -180.162% |
| Indivior PLC | -33.95 Million USD | -36.756% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 17918.938% |
| Flora Growth Corp. | -713 Thousand USD | -6412.135% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -465.309% |
| Evolus, Inc. | 63.7 Million USD | 172.882% |
| HUTCHMED (China) Limited | -197.45 Million USD | 76.485% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 109.691% |
| Akanda Corp. | 3.9 Million USD | 1289.053% |